By group, procedural success and freedom from LVOT obstruction (LVOT mean gradient > 50 mm Hg), the primary efficacy endpoint ...

With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

With volume predicted to rise at ASCs the coming decade, it will be important to keep tabs on outcomes and adverse events.